Health Condition 1: G81- Hemiplegia and hemiparesis Health Condition 2: G811- Spastic hemiplegia
Conditions
Interventions
Intervention1: Vitamin B12 (Methylcobalamine),vitamin B6 (Pyridoxine),vitamin B9 (Folic acid): vitamin B12-0.02-1.5 mg
vitamin B9-0.5-5 mg
Vitamin B6-2-50 mg
Control Intervention1: Standard hospital t
Sponsors
All India Institue of Medical sciences AIIMS Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: 1 Patients who will be having first-ever Ischemic stroke within 72 hours diagnosed by Neurologist with help of CT/MRI report. 2 Patients who will be having hyperhomocysteinemi at baseline. 3 Patients who willbe having normal renal function.
Exclusion criteria
Exclusion criteria: 1 Patients who will be suffering from disease Migraine, Alzheimer dementia, Parkinsonââ?¬•s disease are excluded from the study. 2 Patients with recurrent Ischemic stroke and having significant disabilities are excluded from the study. 3 Patients who having history of vitamin B6, B12, Folic acid supplementations, sex hormonal preparations like androgens intake and treated for depression, dementia, 6 months prior to attack of Ischemic stroke are excluded from the study. 4 Patients who having hypothyroidism, psoriasis, malignancies, rheumatoid disease are excluded from study. 5 Patients who were on treatment with drugs like methotaxate, cyclosporine, theophylline, anticonvulsants like phenytoin, carbamazepine, lipid lowering like cholestyramine, nicotinic acid derivatives (e.g. fenofibrate).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To detect MTHFR, MS, CBS gene polymorphisms among ischemic stroke patients. 2.To determine effect of vitamin B6, B9 , B12 supplementations on homocysteine level among ischemic stroke patients. Timepoint: followup at baseline at 1 month at 2 month and at 4 month | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To determine the reoccurrence of stroke or any major cardiovascular events. 2.To findout correlation of MTHFR, MS, CBS gene polymorphisms with homocysteine level and recurrence of stroke or major cardiovascular events. 3.To findout association of change in homocysteine concentration on stroke severity and functional disability among ischemic stroke patients. 4.To develop and validate a self-instructional discharge module for patients with ischemic stroke. Timepoint: followup at baseline at 1 month at 2 month and at 4 month | — |
Countries
India
Contacts
Public ContactDrRajesh Kumar
AIIMS Rishikesh
Outcome results
None listed